8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                         Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): June 25, 2004



                           Integrated BioPharma, Inc.
                           --------------------------
             (Exact name of registrant as specified in its charter)


           Delaware                      000-28876               22-2407475
           --------                      ---------               ----------
(State or other jurisdiction of    (Commission File Number)     (IRS Employer
 incorporation or organization)                              Identification No.)


           225 Long Avenue
         Hillside, New Jersey                             07205
         --------------------                             -----
(Address of principal executive offices)                (Zip Code)


       Registrant's telephone number, including area code: (973) 926-0816



                                 Not Applicable
          (Former name or former address, if changed since last report)






Item 5.       Other Events and Regulation FD Disclosure.

         On June 25, 2004, Integrated BioPharma, Inc., a Delaware corporation
(the "Company"), issued a press release reiterating that the Company had adopted
a stock repurchase program authorizing the Company to repurchase shares of the
Company's common stock worth up to $3 million, and that the Company was not, at
the time of such press release, aware of any reason for the recent unusual
trading activity affecting its common stock. The press release is attached as an
exhibit to this Report.


Item 7.      Financial Statements and Exhibits

(c) Exhibits.

Exhibit No.  Description
99.1         Press Release issued by Integrated BioPharma, Inc. on June 25, 2004






                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


Date:  June 29, 2004              INTEGRATED BIOPHARMA, INC.


                                  By: /s/ Eric Friedman
                                  Eric Friedman
                                  Vice President and Chief Financial Officer







                                  Exhibit Index

Exhibit No.  Description
99.1         Press Release issued by Integrated BioPharma, Inc. on June 25, 2004

EX-99

                                                                    EXHIBIT 99.1

FOR IMMEDIATE RELEASE                                Contact: Jamie E. Levey
June 25, 2004                                        Investor Relations
                                                     (888) 319-6962

               Integrated BioPharma Adopts Stock Repurchase Plan

HILLSIDE, N.J., June 25, 2004 - Integrated BioPharma, Inc. has adopted a stock
repurchase plan giving management authority to purchase up to $3 million worth
of the company's stock in open market transactions or privately negotiated
transactions at the company's discretion.

In response to the recent trading activity of the company's common stock, the
Company commented that it knows of no reason for the unusual trading activity
affecting its common stock. Integrated BioPharma's management is not aware of
any material adverse change in the business or in the economic fundamentals of
the company.

INB serves the pharmaceutical, biotech and nutraceutical industries. Through
several wholly owned subsidiaries, INB develops, manufactures and distributes
more than 130 products worldwide. Its subsidiary, Paxis Pharmaceuticals, Inc.,
develops and operates a state-of-the-art GMP facility for the production and
sale of paclitaxel and related drugs. Through its biotech subsidiary, NuCycle
Therapy, Inc., INB is developing human therapeutics and preventive cancer
compounds in plants. Further information is available at
http://www.iBioPharma.com.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. Such
statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client. Further information on potential risk factors that could affect the
company's financial results can be found in the company's Reports filed with the
Securities and Exchange Commission.